PSORIASIS-TARGETS AND THERAPY : Impact Factor & More
eISSN: 2230-326XpISSN: 2230-326X
Open AccessShare this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
PSORIASIS-TARGETS AND THERAPY Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in PSORIASIS-TARGETS AND THERAPY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in PSORIASIS-TARGETS AND THERAPY
Inflammaging and Senescence-Associated Secretory Phenotype (SASP) in Psoriasis \u2013 A Narrative Review of Potential Mechanisms and Anti-Inflammaging Strategies
- 28 May 2026
- Psoriasis: Targets and Therapy
Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy
- 27 May 2026
- Psoriasis: Targets and Therapy
Development of Predictive Models for NB-UVB Treatment Efficacy and Safety in Psoriasis
- 25 May 2026
- Psoriasis: Targets and Therapy
Paraneoplastic Papuloerythroderma of Ofuji Masquerading as Worsening Psoriasis
- 22 May 2026
- Psoriasis: Targets and Therapy
Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study
- 12 May 2026
- Psoriasis: Targets and Therapy
Core Differentially Expressed Genes in Psoriasis Lesions: An Integrated Analysis of Four GEO Datasets
- 3 Apr 2026
- Psoriasis: Targets and Therapy
Inflammaging and Senescence-Associated Secretory Phenotype (SASP) in Psoriasis \u2013 A Narrative Review of Potential Mechanisms and Anti-Inflammaging Strategies
- 28 May 2026
- Psoriasis: Targets and Therapy
Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy
- 27 May 2026
- Psoriasis: Targets and Therapy
Development of Predictive Models for NB-UVB Treatment Efficacy and Safety in Psoriasis
- 25 May 2026
- Psoriasis: Targets and Therapy
Paraneoplastic Papuloerythroderma of Ofuji Masquerading as Worsening Psoriasis
- 22 May 2026
- Psoriasis: Targets and Therapy
Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study
- 12 May 2026
- Psoriasis: Targets and Therapy
Core Differentially Expressed Genes in Psoriasis Lesions: An Integrated Analysis of Four GEO Datasets
- 3 Apr 2026
- Psoriasis: Targets and Therapy
FAQs on PSORIASIS-TARGETS AND THERAPY
How long has PSORIASIS-TARGETS AND THERAPY been actively publishing? 
What is the publishing frequency of PSORIASIS-TARGETS AND THERAPY?
How many articles did PSORIASIS-TARGETS AND THERAPY publish last year?
What is the eISSN & pISSN for PSORIASIS-TARGETS AND THERAPY?
Who is the publisher of PSORIASIS-TARGETS AND THERAPY?
